Retatrutide Cost Explained: Monthly, Yearly, and How to Save

Retatrutide at a glance:

• Drug class: Triple agonist (GLP-1, GIP, and glucagon receptors)
• Manufacturer: Eli Lilly
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 6 days
• Receptor target: GLP-1, GIP, and glucagon receptors

Cost is the most common reason people stop Retatrutide, even when it's working. Knowing the full landscape — insurance, savings programs, cash pay, alternatives — usually opens up an option people didn't know they had.

Retatrutide Cash Price

Retatrutide is not consistently available through licensed US pharmacies, so a "list price" is hard to pin down. Compounded or grey-market pricing varies dramatically.

That number is the starting point — what you actually pay depends on:

• Insurance status (commercial, Medicare, Medicaid, uninsured)
• Manufacturer savings programs (where applicable)
• Discount cards (GoodRx, Cost Plus Drug, manufacturer cards)
• Telehealth bundling (some platforms include the drug in a flat monthly fee)
• Pharmacy choice (chain vs independent vs mail-order)

Insurance Coverage

Coverage for Retatrutide depends on the specific plan and the indication being treated. For FDA-approved indications, prior authorization is the most common gate. For off-label use, coverage is generally not available.

The pattern across the GLP-1 / metabolic medication space is: coverage for diabetes is widespread, coverage for weight loss is improving but still inconsistent, and coverage for any off-label use is rare.

Manufacturer Programs

Eli Lilly runs savings programs for eligible patients. Eligibility usually requires commercial insurance and an active prescription. Patients on Medicare or Medicaid generally aren't eligible.

Cash-Pay and Direct-from-Manufacturer Options

Several manufacturers have introduced direct-to-consumer cash channels for their GLP-1 products in response to coverage gaps. These can lower the cash price meaningfully — see our guide to getting GLP-1 medications for current options.

Total Cost Over a Year

A monthly price of $1,000-$1,500 translates to roughly $10,800-$18,000 per year out of pocket without insurance. That's a real number to plan around — many programs that look attractive at $200/month for the first three months reset to full price after the introductory window.

For weight management, the relevant question is whether to plan around long-term use; for GLP-1 medications, weight regain after stopping is well-documented.

Comparing to Alternatives

Currently approved alternatives with comparable evidence include tirzepatide (Zepbound) and semaglutide (Wegovy). Retatrutide is expected to seek FDA approval after phase 3 readout. Some of those alternatives may be cheaper, covered when Retatrutide isn't, or just better-suited for a particular case. See our cost comparison pages: linked above.

Bottom Line

The list price for Retatrutide is real but rarely the final number. Build the cost plan into the treatment plan from day one, and revisit it whenever insurance or savings programs change.

Frequently Asked Questions

Related Reading

• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects
• Retatrutide Results: What the Real Numbers Show in 2026
• Retatrutide for Weight Loss: The Complete 2026 Guide
• How Much Retatrutide Should You Take? A Practical Dosing Guide
• What Retatrutide Really Looks Like Over 12 Months

Sources

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.
• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.

Pricing changes frequently. The numbers on this page reflect publicly available information as of 2026-04-29 and should be verified at the point of purchase.